Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maridebart cafraglutide
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-Protein Conjugates → Peptide Conjugates → Peptides
- Administration
- Subcutaneous
01
Overview
Maridebart cafraglutide (AMG 133, MariTide) is an investigational bispecific biologic developed by Amgen for the treatment of obesity and related cardiometabolic conditions, including atherosclerotic cardiovascular disease (ASCVD) and heart failure. It possesses a unique dual mechanism of action, acting as an agonist of the glucagon-like peptide-1 receptor (GLP-1R) and an antagonist of the gastric inhibitory polypeptide receptor (GIPR). Structurally, the molecule is a peptide-antibody conjugate consisting of two GLP-1 peptide analogues linked to a single monoclonal antibody that serves as the GIPR antagonist. This configuration provides a long half-life of approximately 21 days, enabling a monthly or less frequent subcutaneous dosing schedule. The drug is currently being evaluated in Phase 3 clinical trials, including the MARITIME-CV study focusing on cardiovascular outcomes in patients with ASCVD and obesity or overweight.
- Brand names
- MariTide
- Other names
- maridebart cafraglutideMariTideAMG 133AMG133AMG-133
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on maridebart cafraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maridebart cafraglutide.